5 results on '"Nico van Zandwijk"'
Number of results to display per page
Search Results
2. MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
- Author
-
Ruby C.Y. Lin, Michaela B. Kirschner, Yuen Yee Cheng, Nico van Zandwijk, and Glen Reid
- Subjects
microRNA ,Mesothelioma ,Pathway ,Systems biology ,Therapeutic agents ,Genetics ,QH426-470 - Abstract
Malignant pleural mesothelioma (MPM) is a tumor originating in the mesothelium, the membrane lining the thoracic cavities, and is induced by exposure to asbestos. Australia suffers one of the world's highest rates of MPM and the incidence is yet to peak. The prognosis for patients with MPM is poor and median survival following diagnosis is 4–18 months. Currently, no or few effective therapies exist for MPM. Trials of targeted agents such as antiangiogenic agents (VEGF, EGFR) or ribonuclease inhibitors (ranpirnase) largely failed to show efficacy in MPM Tsao et al. (2009) [1]. A recent study, however, showed that cisplatin/pemetrexed + bevacizumab (a recombinant humanized monoclonal antibody that inhibit VEGF) treatment has a survival benefit of 2.7 months Zalcman et al. (2016) [2]. It remains to be seen if this targeted therapy will be accepted as a new standard for MPM. Thus the unmet needs of MPM patients remain very pronounced and almost every patient will be confronted with drug resistance and recurrence of disease. We have identified unique gene signatures associated with prolonged survival in mesothelioma patients undergoing radical surgery (EPP, extrapleural pneumonectomy), as well as patients who underwent palliative surgery (pleurectomy/decortication). In addition to data published in Molecular Oncology, 2015;9:715-26 (GSE59180) Kirschner et al. (2015) , we describe here additional data using a system-based approach that support our previous observations. This data provides a resource to further explore microRNA dynamics in MPM.
- Published
- 2016
- Full Text
- View/download PDF
3. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009
- Author
-
Matthew J. Soeberg, Nicola Creighton, David C. Currow, Jane M. Young, and Nico van Zandwijk
- Subjects
malignant mesothelioma ,pleural ,peritoneal ,Australia ,incidence ,mortality ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Introduction: Malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPeM) are often grouped together in descriptive epidemiological analyses, resulting in limited understanding of epidemiological patterns for these tumour types. Methods: We studied patterns in the incidence, mortality and survival of people diagnosed with MPM (n=4,076) and MPeM (n=293) in New South Wales (NSW), Australia, 1972–2009. We also calculated 5‐year relative survival for people diagnosed 1972–2006 followed up to 2007. We assessed patterns for each tumour type and histological subtype and, where possible, by combination of these categories. Results: Annual MPM cases steadily increased over time (n=208 in 2009). There was an increasing trend in the MPM age‐standardised incidence rate from 1972 up to 1994. This rate increase has levelled off in the past 10 years. Since 1999, 11 cases of MPeM were diagnosed each year, on average. Five‐year relative survival remained stable for MPM and MPeM. However, 5‐year relative survival in 2002–2006 was substantially higher for people with MPM epithelioid histological subtype (11.7% [95%CI 6.8–18.2%]) compared to all other non‐epithelioid histological subtypes (6.9% [95%CI 5.0–9.1%]), a 70% difference. Survival was also greater for women with MPM (13.4% [95%CI 8.5–19.4%]) compared to men (7.0% [95%CI 5.1–9.2%]). Interpretation: MPM incidence rates have stabilised since the mid‐1990s, suggesting that maximum incidence levels have been reached. When more up‐to‐date data are available, survival estimates should be reanalysed to include people likely to benefit from the wide introduction of combination chemotherapy in 2007, including pemetrexed.
- Published
- 2016
- Full Text
- View/download PDF
4. Chemoprevention of Lung Cancer and Management of Early Lung Cancer
- Author
-
James L. Mulshine, Swati Gulati, and Nico van Zandwijk
- Subjects
Oncology ,medicine.medical_specialty ,Ct screening ,business.industry ,medicine.medical_treatment ,Early lung cancer ,Internal medicine ,medicine ,Smoking cessation ,Early detection ,business ,Lung cancer ,medicine.disease - Published
- 2018
5. Contributors
- Author
-
Alex A. Adjei, Mjung-Ju Ahn, Chris I. Amos, Alberto Antonicelli, Hisao Asamura, Todd Atwood, Paul Baas, Joan E. Bailey-Wilson, David Ball, Fabrice Barlesi, Jose G. Bazan, José Belderbos, Andrea Bezjak, Lucinda J. Billingham, Paolo Boffetta, Martina Bonifazi, Julie R. Brahmer, Elisabeth Brambilla, Fraser Brims, Alessandro Brunelli, Ayesha Bryant, Nicholas Campbell, Brett W. Carter, Robert Cerfolio, Byoung Chul Cho, William C.S. Cho, Hak Choy, Chia-Yu Chu, Glenda Colburn, Henri Colt, Rafael Rosell Costa, Gail E. Darling, Mellar Davis, Patricia M. de Groot, Harry J. de Koning, Paul De Leyn, Dirk De Ruysscher, Ayşe Nur Demiral, Jules Derks, Frank C. Detterbeck, Siddhartha Devarakonda, Anne-Marie C. Dingemans, Jessica S. Donington, Carolyn M. Dresler, Steven M. Dubinett, Grace K. Dy, Jeremy J. Erasmus, Alysa Fairchild, Dean A. Fennell, Hiran C. Fernando, Pier Luigi Filosso, Raja Flores, Kwun Fong, Jesme Fox, David R. Gandara, Leena Gandhi, Laurie Gaspar, Stefano Gasparini, Adi F. Gazdar, Giuseppe Giaccone, Nicolas Girard, Peter Goldstraw, Elizabeth M. Gore, Glenwood Goss, Ramaswamy Govindan, Alissa K. Greenberg, Dominique Grunenwald, Matthias Guckenberger, Swati Gulati, Raffit Hassan, Christopher Hazzard, Fiona Hegi, Thomas Hensing, Roy Herbst, Fred R. Hirsch, Nanda Horeweg, David M. Jablons, James R. Jett, Andrew Kaufman, Paul Keall, Karen Kelly, Feng-Ming (Spring) Kong, Kaoru Kubota, Ite A. Laird-Offringa, Primo N. Lara, Janessa Laskin, Quynh-Thu Le, Cécile Le Péchoux, Elvira L. Liclican, Yolande Lievens, Chia-Chi (Josh) Lin, Billy W. Loo, Michael Mac Manus, Homer A. Macapinlac, Fergus Macbeth, William J. Mackillop, Christopher Maher, Isa Mambetsariev, Sumithra J. Mandrekar, Aaron S. Mansfield, Lawrence B. Marks, Céline Mascaux, Pierre P. Massion, Julien Mazieres, Annette McWilliams, Tetsuya Mitsudomi, Tony Mok, Daniel Morgensztern, Francoise Mornex, James L. Mulshine, Reginald F. Munden, Kristiaan Nackaerts, Shinji Nakamichi, Masayuki Noguchi, Krista Noonan, Silvia Novello, Anna K. Nowak, Kenneth J. O’Byrne, Nisha Ohri, Morihito Okada, Jamie S. Ostroff, Mamta Parikh, Elyse R. Park, Keunchil Park, Harvey I. Pass, Nicholas Pastis, Luis Paz-Ares, Nathan Pennell, Maurice Perol, Rathi N. Pillai, Pieter E. Postmus, Suresh S. Ramalingham, Sara Ramella, Ramón Rami-Porta, Martin Reck, Mary W. Redman, Niels Reinmuth, Umberto Ricardi, David Rice, Carole A. Ridge, William N. Rom, Kenneth E. Rosenzweig, Enrico Ruffini, Valerie W. Rusch, Ravi Salgia, Montse Sanchez-Cespedes, Anjali Saqi, Giorgio V. Scagliotti, Selma Schimmel, Ann G. Schwartz, Suresh Senan, Francis A. Shepherd, Jill M. Siegfried, Gerard A. Silvestri, George R. Simon, Egbert F. Smit, Stephen B. Solomon, Laura P. Stabile, Matthew A. Steliga, Thomas E. Stinchcombe, Nicholas S. Stollenwerk, Jong-Mu Sun, Anish Thomas, Ming-Sound Tsao, Jun-Chieh J. Tsay, Paul Van Houtte, Paul E. Van Schil, Nico van Zandwijk, J.F. Vansteenkiste, Marileila Varella-Garcia, Giulia Veronesi, Shalini K. Vinod, Everett E. Vokes, Heather Wakelee, Tonya C. Walser, Shun-ichi Watanabe, Walter Weder, Benjamin Wei, Ignacio I. Wistuba, James Chih-Hsin Yang, David F. Yankelevitz, Kazuhiro Yasufuku, Ken Y. Yoneda, Gérard Zalcman, Caicun Zhou, Yang Zhou, and Daniel Zips
- Published
- 2018
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.